ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts ...

The design for a medical study in 1743 that was never carried out may have inspired James Lind’s groundbreaking clinical ...

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel ...

Fiduciary Management Inc. (FMI), an independent money management firm, released its “FMI International Equity Strategy ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME Magazine’s 2024 ...

Quoin Pharmaceuticals (QNRX) announces interim clinical data from its ongoing Investigator Pediatric Netherton Syndrome clinical study. The ...

DUBLIN, January 07, 2025 -- ( BUSINESS WIRE )-- ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME Magazine’s 2024 list of ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals ...

ICON (NASDAQ:ICLR) stock fell 8% early Tuesday after it issued financial guidance for 2025. The clinical research ...

At Mayo Clinic, the needs of the patient come first. Part of this commitment involves conducting medical research with the goal of helping patients live longer, healthier lives. Through clinical ...

Royal Bank of Canada reissued their outperform rating on shares of ICON Public (NASDAQ:ICLR – Free Report) in a research report report published on Wednesday morning,Benzinga reports. Royal Bank of ...